Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of “Buy” from Analysts

Vor Biopharma Inc. (NYSE:VOR – Get Rating) has been given a consensus rating of “Buy” by the eight analysts that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $15.93.

A number of equities research analysts recently issued reports on the stock. Robert W. Baird dropped their price objective on shares of Vor Biopharma from $38.00 to $22.00 and set an “outperform” rating for the company in a report on Friday, March 24th. Oppenheimer reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Vor Biopharma in a research report on Friday, March 24th. Stifel Nicolaus decreased their target price on shares of Vor Biopharma from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, March 24th. HC Wainwright decreased their target price on shares of Vor Biopharma from $20.00 to $17.50 and set a “buy” rating on the stock in a research report on Friday, March 24th. Finally, Barclays decreased their target price on shares of Vor Biopharma from $15.00 to $10.00 in a research report on Sunday, March 26th.

Vor Biopharma Price Performance

Shares of VOR opened at $5.11 on Thursday. Vor Biopharma has a 12-month low of $3.48 and a 12-month high of $7.57. The firm has a 50-day moving average price of $4.75 and a 200 day moving average price of $5.27.

Vor Biopharma (NYSE:VOR – Get Rating) last announced its quarterly earnings data on Thursday, March 23rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.03. On average, sell-side analysts anticipate that Vor Biopharma will post -1.76 earnings per share for the current year.

Institutional Trading of Vor Biopharma

Several hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. lifted its position in shares of Vor Biopharma by 104.6% during the fourth quarter. RA Capital Management L.P. now owns 22,748,880 shares of the company’s stock worth $151,280,000 after purchasing an additional 11,627,907 shares in the last quarter. Laurion Capital Management LP lifted its position in shares of Vor Biopharma by 271.3% during the fourth quarter. Laurion Capital Management LP now owns 3,182,889 shares of the company’s stock worth $21,166,000 after purchasing an additional 2,325,581 shares in the last quarter. Artal Group S.A. lifted its position in shares of Vor Biopharma by 422.8% during the fourth quarter. Artal Group S.A. now owns 2,875,581 shares of the company’s stock worth $19,123,000 after purchasing an additional 2,325,581 shares in the last quarter. Millennium Management LLC lifted its position in shares of Vor Biopharma by 47.0% during the fourth quarter. Millennium Management LLC now owns 498,080 shares of the company’s stock worth $3,312,000 after purchasing an additional 159,159 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of Vor Biopharma by 97.1% during the first quarter. BlackRock Inc. now owns 467,598 shares of the company’s stock worth $2,516,000 after purchasing an additional 230,327 shares in the last quarter.

About Vor Biopharma

(Get Rating)

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.